Effects of antileukotriene among asthmatic patients

Abstract

Study objective: To determine the effect of antileukotriene (montelukast) 10 mg once daily for the treatment of mild to moderate asthma. Design: Open label, prospective. Patients: Thirty asthmatic patients ≥18 years of age with baseline FEV1>60 per cent and ≤80 per cent of predicted values and evidence of reversible airway obstruction, as defined by an increase in FEV1 of ≥20 per cent. Interventions: Montelukast 10 mg once daily orally for 12 weeks, back up beta-2 agonist inhaler was available. Measurement and results: Spirometry was performed during the screening period, and every month after starting antileukotriene. Subjects recorded asthma-related symptoms and use of supplement beta-2 agonists daily on diary cards. Over 12 weeks of treatment, the FEV1 increased 10 per cent, 14 per cent and 19 per cent respectively, compared to the baseline (p<0.05). The physician and patients evaluation scores were quite good in the study. Conclusion: Oral montelukast once daily gave a favorable effect in management of mild to moderate asthmatic patients.